en en en en id en en nl en en en en en en en en en en en en en de en fr it en es en sv en ja fr en de pt en ru en en en en cs pl en es ru sv sv en en en en en en en pl en en en fr en en en en en en en en en en de en en en en en de eu en de el en de el en en el en en en en en en en en el en en en en en el en en el en en el en en el en en en en de en en de en en de en en de en en de en en en en en en en en de en en de en en en it en en en en en en en en en es tr en en
For the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
For the treatment of adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
More on this drug: Clinical Trials
Amgen Inc., Thousand Oaks, California
Final clinical guidance report: Blincyto (blinatumomab).
Pharmacoeconomic guidance report: Blincyto (blinatumomab).
Final clinical guidance report: Blincyto (blinatumomab) for Philadelphia chromosome positive acute lymphoblastic leukemia.
Australian public assessment report for blinatumomab.
Australian Government: Department of Health
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity.
Final economic guidance report: Blincyto (blinatumomab) for Philadelphia chromosome positive acute lymphoblastic Leukemia.
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia.
Final clinical guidance report: blinatumomab (Blincyto) resubmission for acute lymphoblastic leukemia.
Final economic guidance report: blinatumomab (Blincyto) resubmission for pediatric acute lymphoblastic leukemia.
Final clinical guidance report: blinatumomab (Blincyto) resubmission for pediatric acute lymphoblastic leukemia.
Final economic guidance report: blinatumomab (Blincyto) resubmission for acute lymphoblastic leukemia.
Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukemia in children and young adults.
Expert Review of Hematology
A systematic review of blinatumomab in the treatment of acute lymphoblastic leukemia: engaging an old problem with new solutions.
Commonly reported adverse events associated with pediatric immunotherapy: a systematic review from the Children’s Oncology Group.
Journal of Pediatric Oncology Nursing
Evidence-based recommendations for nurse monitoring and management of immunotherapy-induced cytokine release syndrome: a systematic review from the Children’s Oncology Group.
Journal of Pediatric Oncology Nursing
Efficacy of targeted immunotherapy as induction or salvage therapy in acute lymphoblastic leukemia: a systematic review and meta-analysis.
Technology in Cancer Research & Treatment
Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis.